Physician profile
Scott William Smith
NPI 1972550283
$67,753.97
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $34K · 2021: $33K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $67,200.00 | 2020-2021 | |
| Novo Nordisk INC | $90.12 | 2019 | |
| Janssen Pharmaceuticals, INC | $75.38 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $67.60 | 2019 | |
| Shire North American Group INC | $40.90 | 2019 | |
| Allergan, INC. | $33.71 | 2019 | |
| Mylan Specialty L.P. | $31.63 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.98 | 2019 | |
| Amgen INC. | $27.18 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.20 | 2019 | |
| Indivior INC. | $21.23 | 2021 | |
| Abbvie INC. | $19.62 | 2019 | |
| Alkermes, INC. | $19.27 | 2020 | |
| Hologic Sales and Service, LLC | $13.30 | 2019 | |
| Merck Sharp & Dohme LLC | $12.66 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $12.48 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.27 | 2019 | |
| Sanofi Pasteur INC. | $11.35 | 2019 | |
| Boston Scientific Corporation | $11.09 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.